nach oben

Current Diabetes Reports

Erschienen in:

01.10.2017 | Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases

verfasst von: Joyce M. Richey, Orison Woolcott

Erschienen in: Current Diabetes Reports | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

The purpose of the review was to revisit the possibility of the endocannabinoid system being a therapeutic target for the treatment of obesity by focusing on the peripheral roles in regulating appetite and energy metabolism.

Recent findings

Previous studies with the global cannabinoid receptor blocker rimonabant, which has both central and peripheral properties, showed that this drug has beneficial effects on cardiometabolic function but severe adverse psychiatric side effects. Consequently, focus has shifted to peripherally restricted cannabinoid 1 (CB1) receptor blockers as possible therapeutic agents that mitigate or eliminate the untoward effects in the central nervous system.

Summary

Targeting the endocannabinoid system using novel peripheral CB1 receptor blockers with negligible penetrance across the blood-brain barrier may prove to be effective therapy for obesity and its co-morbidities. Perhaps the future of blockers targeting CB1 receptors will be tissue-specific neutral antagonists (e.g., skeletal muscle specific to treat peripheral insulin resistance, adipocyte-specific to treat fat excess, liver-specific to treat fatty liver and hepatic insulin resistance).

• Sellayah D, Cagampang FR, Cox RD. On the evolutionary origins of obesity: a new hypothesis. Endocrinology. 2014;155(5):1573–88. This study underscores the need to combat obesity CrossRefPubMed

Apovian CM. The clinical and economic consequences of obesity. Am J Manag Care. 2013;19(11):S219–S28.

Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med. 2007;120(9 Suppl 1):S10–6. discussion S6-7CrossRefPubMed

Haffner SM. Type 2 diabetes and the metabolic syndrome: National Cholesterol Education Program guidelines and supporting evidence. Crit Pathw Cardiol. 2004;3(3 Suppl):S12-4.CrossRefPubMed

Cervino C, Pasquali R, Pagotto U. Cannabinoid receptor antagonists and the metabolic syndrome: novel promising therapeutical approaches. Mini-Rev Med Chem. 2007;7(1):21–30.CrossRefPubMed

Bellocchio L, Mancini G, Vicennati V, Pasquali R, Pagotto U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol. 2006;6(6):586–91.CrossRefPubMed

Despres JP, Lemieux I, Almeras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes. 2006;30:S44–52.CrossRef

Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal-transduction. Proc Natl Acad Sci U S A. 1993;90(16):7656–60.CrossRefPubMedPubMedCentral

Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.CrossRefPubMed

10.

Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010;62(4):588–631.CrossRefPubMedPubMedCentral

11.

Piomelli D. More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology. 2014;76 Pt B:228–34.CrossRefPubMed

12.

Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem. 2008;283(48):33021–5.CrossRefPubMedPubMedCentral

13.

Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8(5):585–9.CrossRefPubMed

14.

Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord. 2003;27(3):289–301.CrossRefPubMed

15.

Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423–31.CrossRefPubMedPubMedCentral

16.

Kunos G, Osei-Hyiaman D, Bátkai S, Sharkey KA, Makriyannis A. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci. 2009;30(1):1–7.CrossRefPubMed

17.

Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120(8):2953–66.CrossRefPubMedPubMedCentral

18.

Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54(10):2838–43.CrossRefPubMedPubMedCentral

19.

Mechoulam R, Devane WA, Glaser R. Cannabinoid geometry and biological activity. In: Nahas G, Sutin KM, Harvey D, Agurell S, Pace N, Camcro R, editors. Marihuana and Medicine. Ottawa: Humana Press; 1999. p. 65-90.

20.

Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359(1):1–18.CrossRefPubMed

21.

Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother. 1993;27(7–8):827–31.CrossRefPubMed

22.

Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci. 2008;29(5):229–33.CrossRefPubMed

23.

Matias I, Di Marzo V. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Investig. 2006;29(3 Suppl):15–26.

24.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, Group R-ES. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389–97.CrossRefPubMed

25.

Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008;31(Suppl 2):S229–40.CrossRefPubMed

26.

Despres JP, Golay A, Sjostrom L. Rimonabant Obesity Lipids Study G. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121–34.CrossRefPubMed

27.

Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol. 2007;293(6):R2185–93.CrossRefPubMed

28.

Ward SJ, Raffa RB. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring). 2011;19(7):1325–34.CrossRef

29.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, Group R-NAS. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761–75.CrossRefPubMed

30.

Scheen AJ. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol. 2008;20(Suppl 1):139–46.CrossRefPubMed

31.

Ducobu J, Sternon J. Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system. J Pharm Belg. 2005;60(3):89–91.PubMed

32.

Di Marzo V, Szallasi A. Rimonabant in rats with a metabolic syndrome: good news after the depression. Br J Pharmacol. 2008;154(5):915–7.CrossRefPubMedPubMedCentral

33.

Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes. 2007;31(4):692–9.

34.

Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, Cartier A, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia. 2009;52(2):213–7.CrossRefPubMed

35.

Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S66–78.CrossRefPubMed

36.

Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;51(8):1356–67.CrossRefPubMed

37.

Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring). 2008;16(3):553–65.CrossRef

38.

Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol. 2007;18(2):129–40.CrossRefPubMed

39.

Herling AW, Kilp S, Juretschke HP, Neumann-Haefelin C, Gerl M, Kramer W. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes. 2008;32(9):1363–72.CrossRef

40.

Richey JM, Woolcott OO, Stefanovski D, Harrison LN, Zheng D, Lottati M, et al. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs. Am J Physiol Endocrinol Metab. 2009;296(6):E1311–8.CrossRefPubMedPubMedCentral

41.

Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia. 2001;44(3):312–9.CrossRefPubMed

42.

Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta. 2008;1781(4):200–12.CrossRefPubMed

43.

Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A. 2001;98(11):6402–6.CrossRefPubMedPubMedCentral

44.

•• Argueta DA, DiPatrizio NV. Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. Physiol Behav. 2017;171:32–9. Study demonstrates enhanced endocannabinoid signaling at peripheral CB1 receptors with fat feeding CrossRefPubMed

45.

Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298–305.CrossRefPubMedPubMedCentral

46.

Hansen HS, Artmann A. Endocannabinoids and nutrition. J Neuroendocrinol. 2008;20(Suppl 1):94–9.CrossRefPubMed

47.

Engeli S, Lehmann AC, Kaminski J, Haas V, Janke J, Zoerner AA, et al. Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects. Obesity (Silver Spring). 2014;22(5):E70–6.CrossRef

48.

Kim SP, Woolcott OO, Hsu IR, Stefanoski D, Harrison LN, Zheng D, et al. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs. Am J Physiol Endocrinol Metab. 2012;302(10):E1261–8.CrossRefPubMedPubMedCentral

49.

Kabir M, Stefanovski D, Hsu IR, Iyer M, Woolcott OO, Zheng D, et al. Large size cells in the visceral adipose depot predict insulin resistance in the canine model. Obesity (Silver Spring). 2011;19(11):2121–9.CrossRef

50.

Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28(4):640–8.CrossRefPubMed

51.

Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 2005;19(11):1567–9.PubMed

52.

Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439–51.CrossRefPubMed

53.

•• Kabir M, Iyer MS, Richey JM, Woolcott OO, Asare Bediako I, Wu Q, et al. CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors. Am J Physiol Endocrinol Metab. 2015;309(8):E747–58. Study demonstrates the importance of adiponectin in improving insulin sensitivity with CB1 antagonism CrossRefPubMedPubMedCentral

54.

Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology. 2008;149(5):2557–66.CrossRefPubMed

55.

Bellocchio L, Cervino C, Pasquali R, Pagotto U. The endocannabinoid system and energy metabolism. J Neuroendocrinol. 2008;20(6):850–7.CrossRefPubMed

56.

Kunos G, Osei-Hyiaman D. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol. 2008;294(5):G1101–4.CrossRefPubMed

57.

Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008;118(9):3160–9.CrossRefPubMedPubMedCentral

58.

Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55(11):3053–60.CrossRefPubMedPubMedCentral

59.

Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem. 2005;280(26):25196–201.CrossRefPubMed

60.

Kola B, Wittman G, Bodnár I, Amin F, Lim CT, Oláh M, et al. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. FASEB J. 2013;27(12):5112–21.CrossRefPubMedPubMedCentral

61.

Gamelin FX, Aucouturier J, Iannotti FA, Piscitelli F, Mazzarella E, Aveta T, et al. Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity. J Physiol Biochem. 2016;72(2):183–99.CrossRefPubMed

62.

Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res. 2006;38(5):356–8.CrossRefPubMed

63.

Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes. 2008;57(11):2977–91.CrossRefPubMedPubMedCentral

64.

•• Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013;23(17):4751–60. This study provides a nice description of peripheral CB1 blockade CrossRefPubMed

65.

Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, Antoniou K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19(12):pyw068.CrossRefPubMedPubMedCentral

66.

Knani I, Earley BJ, Udi S, Nemirovski A, Hadar R, Gammal A, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 2016;5(12):1187–99.CrossRefPubMedPubMedCentral

67.

Chorvat RJ, Berbaum J, Seriacki K, McElroy JF. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012;22(19):6173–80.CrossRefPubMed

68.

•• Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol. 2013;76(6):846–57. Study provides evidence for minimal brain penetrance of a CB1 blocker in humans CrossRefPubMedPubMedCentral

69.

•• Takano A, Gulyas B, Varnas K, Little PB, Noerregaard PK, Jensen NO, et al. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study. Synapse. 2014;68(3):89–97. Study provides promising results for second-generation CB1 antagonism as an anti-obesity drug CrossRefPubMed

70.

Hung M-S, Chang C-P, Li T-C, Yeh T-K, Song J-S, Lin Y, et al. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist. Chem Med Chem. 2010;5(9):1439–43.CrossRefPubMed

71.

Mastinu A, Pira M, Pinna GA, Pisu C, Casu MA, Reali R, et al. NESS06SM reduces body weight with an improved profile relative to SR141716A. Pharmacol Res. 2013;74:94–108.CrossRefPubMed

72.

Lazzari P, Serra V, Marcello S, Pira M, Mastinu A. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats. Eur Neuropsychopharmacol. 2017;27(7):667–78.CrossRefPubMed

73.

Rossi F, Bellini G, Luongo L, Manzo I, Tolone S, Tortora C, et al. Cannabinoid receptor 2 as antiobesity target: inflammation, fat storage, and Browning modulation. J Clin Endocrinol Metab. 2016;101(9):3469–78.CrossRefPubMed

74.

Verty AN, Stefanidis A, McAinch AJ, Hryciw DH, Oldfield B. Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. PLoS One. 2015;10(11):e0140592.CrossRefPubMedPubMedCentral

75.

LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett. 2009;19(3):639–43.CrossRefPubMed

76.

Matthews JM, McNally JJ, Connolly PJ, Xia M, Zhu B, Black S, et al. Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists. Bioorg Med Chem Lett. 2016;26(21):5346–9.CrossRefPubMed

77.

Gonzalez-Mariscal I, Krzysik-Walker SM, Doyle ME, Liu QR, Cimbro R, Santa-Cruz Calvo S, et al. Human CB1 receptor isoforms, present in hepatocytes and beta-cells, are involved in regulating metabolism. Sci Rep. 2016;6:33302.CrossRefPubMedPubMedCentral

78.

Dow RL, Carpino PA, Gautreau D, Hadcock JR, Iredale PA, Kelly-Sullivan D, et al. Design of a potent CB1 receptor antagonist series: potential scaffold for peripherally-targeted agents. ACS Med Chem Lett. 2012;3(5):397–401.CrossRefPubMedPubMedCentral

Titel: Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases
verfasst von: Joyce M. Richey
Orison Woolcott
Publikationsdatum: 01.10.2017
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 10/2017
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-017-0924-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Cardiovascular and Mortality Risks in Migrant South Asians with Type 2 Diabetes: Are We Winning the Battle?

Application of One-Step IADPSG Versus Two-Step Diagnostic Criteria for Gestational Diabetes in the Real World: Impact on Health Services, Clinical Care, and Outcomes

The Immune System in Obesity: Developing Paradigms Amidst Inconvenient Truths

Tolerogenic Nanoparticles to Treat Islet Autoimmunity

Animal Models of Diabetic Retinopathy